Skip to content

Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease

Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03445624
Enrollment
60
Registered
2018-02-26
Start date
2018-07-01
Completion date
2021-10-01
Last updated
2023-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Diseases

Brief summary

assessment of inflammatory bowel disease patients in activity and remission by abdominal ultrasound examine non-invasive and in physiological condition by measuring the colon wall thickness in diagnosis and follow up the patient also including extra intestinal features such as the splanchnic vessels,mesentery and lymph nodes . Doppler u.s can evaluate bowel wall vascularity In activity and remission . peripheral hemogram in relationship to activity inflammatory bowel disease asses anemia ,increase monocyte and decrease mean platelet volume( MPV) . also,the investigator will evaluate the outcome of different lines of treatment traditional and biologic therapy (response to treatment,times of activity and complications)

Detailed description

the participants will follow up the patient for 1 year in the first visit All patients in this study will be subjected to: 1. Detailed history. 2. Careful physical examination 3. laboratory investigation 1. complete blood picture. 2. liver function 3. kidney function 4. Iron profile(serum iron ,serum ferritin 5. ESR (erythrocyte sedimentation rate ) g-CRP (C reactive protein) f-LDH (lactate dehydrogenase) 4. Abdominal us(the colon wall thickness,lymph nodes,mass,other organs) 5. Doppler us (mesenteric vessels) 6. colonoscopy after 1 year of treatment follow up every 3 months by abdominal US and peripheral hemogram and last visit after 1 year colonoscopy and biopsy for assessment response to treatment

Interventions

DRUGInfliximab

follow up the patients who received this drugs for 1 year by abdominal ultrasound,peripheral hemogram and colonoscopy

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
15 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* patients diagnosed ulcerative colitis at age(15-60) * patients diagnosed crohns disease at age(15-60)k

Exclusion criteria

* liver cirrhosis and portal hypertension * spontaneous bacterial peritonitis * Ischemic colitis

Design outcomes

Primary

MeasureTime frameDescription
the role abdominal ultrasound in assessment inflammatory bowel disease2 yearmeasure the thickness of the colon by abdominal ultrasound and doppler mesenteric vessels .more than 4ml detect activity doppler mesenteric highly vascularity in activity

Other

MeasureTime frameDescription
Assesment inflammatory bowel disease by complete blood picture2yearfollow up haemoglobin level (less than 10 mg) indicate anemia which mean the patient uncontrolled monocyte( monocyte more than 12% of white blood cell count detect activity) Mean platelet volume less than 6 fl which decrease in activity inflammatory bowel disease

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026